Protalix BioTherapeutics, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing was signed March 12, 2015. This is an annual report, not a standalone quarterly filing; selected quarterly data are unaudited.
Business context
Protalix develops recombinant therapeutic proteins using its plant-cell ProCellEx platform. Its principal commercial product is taliglucerase alfa (Elelyso in the U.S. and Israel; Uplyso in Brazil) for Gaucher disease. Pfizer commercializes it in most markets; Protalix retained commercial rights in Israel and Brazil. The company’s pipeline includes PRX-102 for Fabry disease and oral or inhaled candidates PRX-106, PRX-110 and PRX-112.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $13.651 million | $10.479 million |
| Company share of Pfizer collaboration | $1.509 million | $1.034 million |
| Cost of revenue | $9.053 million | $5.428 million |
| Gross profit | $6.107 million | $6.085 million |
| Net R&D expense | $21.650 million | $24.816 million |
| Selling, general and administrative expense | $9.661 million | $8.385 million |
| Net financial expense | $4.739 million | $0.674 million |
| Net loss | $29.943 million | $27.790 million |
| Net loss per share | $0.32 | $0.30 |
| Operating cash flow | $(29.281) million | $(30.653) million |
| Cash and cash equivalents at year-end | $54.767 million | $86.398 million |
| Total assets / total liabilities | $78.470 million / $134.071 million | $113.333 million / $140.279 million |
FY 2014 revenue rose about 30%, including $5.2 million of Israeli product sales and $3.5 million of sales to Fiocruz in Brazil. The filing also reports $4.563 million of annual amortization of Pfizer upfront and milestone payments. Gross profit was nearly flat despite higher cost of revenue; the reported gross profit equals about 44.7% of stated revenue, before considering the separately presented collaboration share.
Net R&D expense declined about 13%, while SG&A rose about 15%, primarily due to sales and marketing costs associated with Brazil. Financial expense increased substantially, mainly reflecting $3.1 million of interest expense on the 4.5% convertible notes and approximately $1.3 million of foreign-exchange losses. Cash fell by $31.631 million during the year. Investing cash outflow was $1.001 million; financing cash inflow was only $46,000.
At year-end, current assets were $65.520 million and current liabilities were $26.210 million, implying working capital of about $39.310 million. The company reported $67.464 million of convertible notes on its balance sheet; the notes have $69 million aggregate principal, bear 4.5% interest and mature September 15, 2018. Contractual obligations totaled $90.609 million, including $81.420 million associated with the notes. Capital deficiency was $55.601 million.
Material developments and outlook
- FDA approval of Elelyso for pediatric patients was obtained in August 2014. Brazil’s CONITEC issued a positive funding recommendation for Uplyso for adult Gaucher patients in September 2014.
- The Fiocruz supply and technology-transfer agreement became effective in January 2014. Fiocruz committed to purchases of approximately $40 million during the first two years and at least approximately $40 million annually thereafter; Protalix recorded $3.5 million of 2014 sales under the arrangement. A first-quarter 2015 order was approximately $5.7 million, of which about $1.7 million had been delivered by the filing date. Failure to meet purchase commitments could allow Protalix to terminate the agreement.
- Management’s January 2015 strategy prioritized candidates it believes may offer a clear clinical advantage. For PRX-102, management expected interim 1 mg/kg results in Q3 2015, full dose-group results in Q4 2015 and a potential Phase III start in early 2016. It planned proof-of-concept efficacy studies for PRX-106 and PRX-110 during 2015, with results expected in early 2016, and further formulation work on PRX-112.
- Management stated that available cash was expected to fund planned operations for at least 12 months, but cautioned that estimates depend on assumptions and that additional capital may be required. It expects R&D to remain its primary expense. No specific revenue or earnings guidance was provided.
- PRX-102 interim results described in the filing were based on small patient groups and early follow-up. One of 12 patients in the safety analysis discontinued after hypersensitivity; the filing reports generally mild or moderate adverse events. These findings are preliminary and do not establish later-stage efficacy or safety.
Risks, contingencies and unusual items
- Commercial performance depends heavily on taliglucerase alfa, Pfizer’s execution outside Israel and Brazil, and Fiocruz’s purchases and performance. Competition includes established Gaucher therapies and Fabry treatments. The filing notes that EU orphan exclusivity for VPRIV impeded taliglucerase alfa’s EU authorization prospects.
- Ongoing losses and cash use, debt service, and uncertain access to future financing could constrain clinical programs or require dilutive financing. The filing reports approximately $138.8 million of tax-loss carryforwards, including approximately $16.9 million potentially subject to U.S. ownership-change limits; deferred tax assets were fully reserved.
- Protalix had approximately $30 million of contingent OCS grant repayment/royalty exposure at year-end, subject to the terms of Israeli government funding. Manufacturing outside Israel or transfer of funded technology may require approvals and could increase royalty obligations.
- Manufacturing quality, reliance on third-party fill-and-finish providers and certain single-source materials, regulatory approvals, clinical trial outcomes, reimbursement, intellectual-property challenges, and political or security disruptions in Israel are material risks.
- Inventory write-downs were $1.7 million in 2014. The filing also reports $1.3 million of foreign-exchange losses and $3.1 million of contractual note interest expense. No material legal proceedings or off-balance-sheet arrangements were reported.
Most important facts to verify
- Confirm the composition, timing and collectability of 2014 revenue, particularly Fiocruz purchases, Pfizer collaboration economics and the recurring amortization of deferred Pfizer payments.
- Review cash runway assumptions against the $29.3 million operating cash outflow, planned clinical spending, note interest and 2018 maturity obligations.
- Track Fiocruz’s minimum-purchase performance, subsequent orders and delivery status, and the related Pfizer payment and agent-fee terms.
- Assess full PRX-102 trial results, later-stage study plans and regulatory feedback; distinguish preliminary small-cohort findings from confirmatory evidence.
- Reconcile the selected quarterly data: Q4 2014 lists net income of $8.469 million but loss per share of $0.09, which appear inconsistent. The filing text does not provide a clear explanation for this discrepancy.
- Verify debt carrying value versus principal, conversion terms and future funding needs; also monitor the OCS contingent exposure and any manufacturing or technology-transfer approvals.